Text full multimedia monochrome

First time here?

Find out more about how The Lecture List works.

Coronavirus situation update

Our lecture organisers may or may not have had time to update their events with cancellation notices. Clearly social gatherings are to be avoided and that includes lectures. STAY AT HOME FOLKS, PLEASE.

Help!

Find out what you can do to keep The Lecture List online

Bad Pharma: How drug companies distort science

Ben Goldacre will put the $600bn global pharmaceutical industry under the microscope.


Doctors and patients need good scientific evidence to make informed decisions. But instead, companies run bad trials on their own drugs, which distort and exaggerate the benefits by design. When these trials produce unflattering results, the data is simply buried. All of this is perfectly legal. In fact, even government regulators withhold vitally important data from the people who need it most. Doctors and patient groups have stood by too, and failed to protect us. Instead, they take money and favours, in a world so fractured that medics and nurses are now educated by the drugs industry. Patients are harmed in huge numbers.

In this new talk, Ben Goldacre will put the $600bn global pharmaceutical industry under the microscope. He will present a clear and witty attack, showing exactly how the science has been distorted, how our systems have been broken, and how easy it would be to fix them. For more information and to book visit www.rigb.org


Speaker(s):

Dr Ben Goldacre | talks | www

 

Date and Time:

2 October 2012 at 7:00 pm

Duration:

1 hour 30 minutes

 

Venue:

The Royal Institution of Great Britain
21 Albemarle Street
London
W1S 4BS
+44 20 74 09 29 92
http://www.rigb.org/

More at The Royal Institution of Great Britain...

 

Tickets:

£10 standard, £7 concessions and £5 Associates. Members go free.

Available from:

www.rigb.org

Register to tell a friend about this lecture.

Comments

If you would like to comment about this lecture, please register here.



 

Any ad revenue is entirely reinvested into the Lecture List's operating fund